The influence of hepatitis B virus infection on patients undergoing allogeneic hematopoietic stem cell transplantation.
- Author:
Chen LIANG
1
;
Er-Lie JIANG
;
Yong HUANG
;
Zhang-Song YAN
;
Dong-Lin YANG
;
Yi HE
;
Qiao-Ling MA
;
Jia-Lin WEI
;
Mei WANG
;
Si-Zhou FENG
;
Lu-Gui QIU
;
Ming-Zhe HAN
Author Information
- Publication Type:Journal Article
- MeSH: Hematopoietic Stem Cell Transplantation; Hepatitis B; epidemiology; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans
- From: Chinese Journal of Hematology 2010;31(7):456-460
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the prognosis and hepatitis B serologic marker changes in patients with HBV infection or with HBV infected donors after allogenic hematopoietic stem cell transplantation (allo-HSCT).
METHODSThe clinical outcomes of 79 patients receiving allo-HSCT, including 55 with HBV infection and 24 from HBV infected donors were analyzed retrospectively.
RESULTS(1) HBV infection did not interfere with the clinical outcome of allo-HSCT. (2) In 20 HBsAg(+) patients, 13(65.0%) developed HBV reactivation between 0.5 and 10 months after transplantation, 9(45.0%) developed HBV-related hepatitis. (3) For the 35 HBsAg(-) and HBcAb/HBeAb positive patients, 4 (11.4%) occurred HBV seroconversion, 1 of the 4 complicated with severe chronic graft-versus-host disease (cGVHD). (4) There was a significant difference in HBV reactivation rate between the HBsAg(+) and HBsAg-groups (P < 0.01). The incidence of hepatitis occurred within 100 days after HSCT was high in HBsAg(+) patients (P < 0.05). (5) Clearance of HBsAg was observed in 2 HBsAg(+) patients, both of whom received graft from HBsAb positive donors.
CONCLUSIONSDonors or recipients infected with HBV is not considered an absolute contraindication for HSCT, but HBsAg positivity is a high risk factor for HBV reactivation and prophylactic lamivudine treatment may be helpful. For patients with HBcAb/HBeAb positivity, seroconversion can be observed, especially after immunosuppressant withdrawal. Adoptive immunity is effective in clearing HBV in these patients.